Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
728 results
  • Felbamate add-on therapy for drug-resistant focal epilepsy. [Journal Article]
    Cochrane Database Syst Rev 2019; 8:CD008295Shi LL, Bresnahan R, … Geng J
  • CONCLUSIONS: In view of the methodological deficiencies, the limited number of included studies and the differences in outcome measures, we have found no reliable evidence to support the use of felbamate as an add-on therapy in people with drug-resistant focal-onset epilepsy. A large-scale, randomised controlled trial conducted over a longer period of time is required to inform clinical practice.
  • [Epilepsy and breastfeeding: from myth to reality]. [Review]
    Rev Neurol 2019; 69(2):68-76Cabo-Lopez I, Canneti B, Puy-Nunez A
  • CONCLUSIONS: Very few AEDs are incompatible with breastfeeding. The decision to breastfeed should take into account not only the AED, but also its number, dose, serum levels, transmission and elimination rates in the infant, and the conditions of the newborn infant. Ethosuximide and felbamate are probably high risk and incompatible with breastfeeding. Lamotrigine, phenobarbital, pregabalin, primidone, tiagabine, eslicarbazepine, brivaracetam, perampanel, zonisamide, lacosamide or the sporadic use of benzodiazepines in low doses are considered quite safe, with a low risk for breastfeeding. The other AEDs present a very low risk for breastfeeding.
  • StatPearls: Felbamate [BOOK]
    StatPearls Publishing: Treasure Island (FL) Hanrahan Brian B Vanderbilt University Medical Center Carson Robert P. RP Vanderbilt University Medical Center BOOK
  • Felbamate is an anti-epileptic drug (AED) that was approved by the Food and Drug Administration (FDA) in 1993 for the management of focal seizures and Lennox-Gastaut syndrome. Several small class III studies have suggested felbamate may be an effective treatment for absence seizures, juvenile myoclonic epilepsy, and infantile spasms.[1]
  • The pharmacological management of Lennox-Gastaut syndrome and critical literature review. [Review]
    Seizure 2018; 63:17-25Verrotti A, Striano P, … Curatolo P
  • Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy with a prevalence of 1-2% of all patients with epilepsy. It is characterized by multiple pharmaco-resistant seizure types, including tonic, atypical absences and tonic or atonic drop attacks, and the presence of electroencephalographic abnormalities, such as slow-spike waves and paroxysmal fast rhythms. Intellectual disability, be…
  • Drugs and Lactation Database (LactMed): Felbamate [BOOK]
    National Library of Medicine (US): Bethesda (MD)BOOK
  • Because no information is available on the use of felbamate during breastfeeding, and because it can cause potentially fatal hematologic and hepatic toxicities, authors of authoritative reviews recommend that breastfeeding not be undertaken during maternal felbamate therapy until more safety data are available.[1][2]
New Search Next